-
The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired
Thursday, June 8, 2017 - 10:05am | 445Read More...As Juno Therapeutics Inc (NASDAQ: JUNO) continues to trail its peers, BTIG analyst Dane Leone sees the stock falling nearly 50 percent as he downgrades his rating to Sell and set a price target of $12 (see Dane Leone's track record). “The company is trailing peers [Kite Pharma Inc (NASDAQ:...
-
11 Biopharma CEOs To Follow On Twitter
Thursday, August 18, 2016 - 10:52am | 613Read More...Twitter Inc (NYSE: TWTR) can be an extremely useful and tradable tool for investors, but only if you follow the right people. Here’s a look at 11 biotech and pharmaceutical company CEOs that have the potential for market-moving tweets. 1. Brent Saunders - @brentlsaunders Saunders is...
-
Juno Therapeutics CEO Weighs In On Celgene Partnership, T-Cell Innovations
Tuesday, June 30, 2015 - 1:21pm | 364Read More...Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics Inc (NASDAQ: JUNO) recently announced a 10-year collaborative partnership to develop T-cell immunotherapies, under which the former will be buying $1 billion stake in the latter at $93 per share. Hans Bishop, Juno Therapeutics CEO, was on...
-
What Sets Juno Therapeutics Inc Apart In Immunotherapy Space?
Wednesday, January 14, 2015 - 2:41pm | 371Read More...Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have performed well since the company got listed on December 19, up more than 50 percent. Hans Bishop, Juno Therapeutics co-founder and CEO, was on CNBC to discuss what differentiates Juno from other companies competing in the immunotherapy space and...
